Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (3348)	10/22/2005 3:52:33 PM
From: scaram(o)uche	Respond to of 12215

>> Clinical Cell and Vaccine Production Facility << completely cool. exactly where this sort of work SHOULD be done, in an academic environment. >> First Law << Please, scale it back. I am completely enthusiastic about efforts to immunize against cancers. There are some studies that are destined to fail imo, and there are others that are smoke-screening two variables as one in the name of "autologous vaccine". But there are few studies that I know of which are flat-out not worth pursuing. a continuing focus on "destined to fail" is not correct, according to how I feel. Good stuff, that Penn study. Penn has always been a home to practical immunobiology, IMO. Thanks! Rick